Abstract:The gut-liver axis covers the bidirectional communication between the gut and the liver, and thus includes signals from liver-to-gut (e.g., bile acids, immunoglobulins) and from gut-to-liver (e.g., nutrients, microbiota-derived products, and recirculating bile acids). In a healthy individual, liver homeostasis is tightly controlled by the mostly tolerogenic liver resident macrophages, the Kupffer cells, capturing the gut-derived antigens from the blood circulation. However, disturbances of the gut-liver axis have been associated to the progression of varying chronic liver diseases, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and primary sclerosing cholangitis. Notably, changes of the gut microbiome, or intestinal dysbiosis, combined with increased intestinal permeability, leads to the translocation of gut-derived bacteria or their metabolites into the portal vein. In the context of concomitant or subsequent liver inflammation, the liver is then infiltrated by responsive immune cells (e.g., monocytes, neutrophils, lymphoid, or dendritic cells), and microbiota-derived products may provoke or exacerbate innate immune responses, hence perpetuating liver inflammation and fibrosis, and potentiating the risks of developing cirrhosis. Similarly, food derived antigens, bile acids, danger-, and pathogen-associated molecular patterns are able to reshape the liver immune microenvironment. Immune cell intracellular signaling components, such as inflammasome activation, toll-like receptor or nucleotide-binding oligomerization domain-like receptors signaling, are potent targets of interest for the modulation of the immune response. This review describes the current understanding of the cellular landscape and molecular pathways involved in the gut-liver axis and implicated in chronic liver disease progression. We also provide an overview of innovative therapeutic approaches and current clinical trials aiming at targeting the gut-liver axis for the treatment of patients with chronic liver and/or intestinal diseases.

Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy

Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases

Crosstalk Between Liver Macrophages and Gut Microbiota: an Important Component of Inflammation-Associated Liver Diseases

Gut microbiota in non‐alcoholic fatty liver disease and alcohol‐related liver disease: Current concepts and perspectives

Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond

The Gut Microbiota: How Does It Influence the Development and Progression of Liver Diseases

Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg

Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease

[The gut-liver axis: how the gut promotes liver disease]

Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature

The gut-liver nexus: exploring gut microbiota dysbiosis in non-alcoholic fatty liver disease and its therapeutic implications

Gut‐liver axis‐mediated mechanism of liver cancer: A special focus on the role of gut microbiota

The gut–liver axis and the intersection with the microbiome

NAFLD/MASLD and the Gut-Liver Axis: From Pathogenesis to Treatment Options

Gut–Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers

Microbiota and Gut–Liver Axis: An Unbreakable Bond?

Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances

The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases

The role of the microbiome in liver disease

The gut-liver axis in immune remodeling of hepatic cirrhosis

Gut microbiome in non-alcoholic fatty liver disease associated hepatocellular carcinoma: Current knowledge and potential for therapeutics